FGFR1 is a cell surface receptor overexpressed by several tumors, including breast, lung, ovarian, head and neck and bladder cancers and constitutes an attractive tumor marker for development of targeted therapeutics [44]. This evidence concerns the gene CD177 and neoplasm.